deltatrials
Unknown PHASE1 INTERVENTIONAL 1-arm NCT05198817

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SHR-2002 Injection or in Combination With Other Anti-cancer Therapy in Advanced Malignant Tumors of Patients

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Conditions Advanced Malignant Tumors
Interventions SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
Updated 6 times since 2022 Last updated: Jun 26, 2022 Started: Feb 22, 2022 Primary completion: Jan 31, 2023 Completion: Jun 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Malignant Tumors and is currently ongoing. Suzhou Suncadia Biopharmaceuticals Co., Ltd. leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshotEnrolling By Invitation~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 19 months · monthly snapshotUnknown~Jan 2026 – present · 3 months · monthly snapshot

Change History

6 versions recorded

  1. Jan 2026 — Present [monthly]

    Unknown PHASE1

  2. Sep 2024 — Present [monthly]

    Unknown PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1

    Status: Enrolling By Invitation → Unknown

  4. Jul 2022 — Jul 2024 [monthly]

    Enrolling By Invitation PHASE1

  5. May 2022 — Jul 2022 [monthly]

    Enrolling By Invitation PHASE1

    Status: Not Yet Recruiting → Enrolling By Invitation

▶ Show 1 earlier version

  1. Feb 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Data source: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations